Vinorelbine

Vinorelbine is an anti-mitotic agent which inhibits the proliferation of Hela cells with IC50 of 1.25 nM.

Product Specifications

CAS Number

[71486-22-1]

Product Name Alternative

KW-2307 base

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Autophagy; Microtubule/Tubulin

Type

Natural Products

Related Pathways

Autophagy; Cell Cycle/DNA Damage; Cytoskeleton

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/vinorelbine.html

Solubility

10 mM in DMSO

Smiles

CC[C@@]1(C=CCN2CC3)[C@@]2([H])[C@@]3(C(C=C([C@](C4=C5C(C=CC=C6)=C6N4)(C[C@@](C=C(CC)C7)([H])C[N@]7C5)C(OC)=O)C(OC)=C8)=C8N9C)[C@]9([H])[C@](C(OC)=O)(O)[C@@H]1OC(C)=O

Molecular Formula

C45H54N4O8

Molecular Weight

778.93

Precautions

H302, H315, H319, H335

References & Citations

[1]Ngan VK, et al. Mechanism of mitotic block and inhibition of cell proliferation by the semisynthetic Vinca alkaloids vinorelbine and its newer derivative vinflunine. Mol Pharmacol. 2001 Jul;60 (1) :225-32.|[2]Liu XM, et al. Unique induction of p21 (WAF1/CIP1) expression by vinorelbine in androgen-independent prostate cancer cells. Br J Cancer. 2003 Oct 20;89 (8) :1566-73.|[3]Poirier VJ, et al. Toxicity, dosage, and efficacy of vinorelbine (Navelbine) in dogs with spontaneous neoplasia. J Vet Intern Med. 2004 Jul-Aug;18 (4) :536-9.|[4]Pierro JA, et al. Phase I clinical trial of vinorelbine in tumor-bearing cats. J Vet Intern Med. 2013 Jul-Aug;27 (4) :943-8.